EBR Systems (ASX:EBR) said that its WiSE cardiac resynchronization therapy system was implanted in the first commercial patients in the US, following approval from the Food and Drug Administration, according to a Friday Australian bourse filing.
Reimbursement add-on payments for both inpatients and outpatients are expected to begin in October, the filing said.
The initiation of its limited market release is also expected in October, running into 2026, aimed at developing clinician advocacy and facilitating wider adoption.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.